• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Novakand Pharma Provides an Operational Update Regarding Management, Website, and Planned Extraordinary General Meeting

KanceraPress release16.07.2026, 10.40

Novakand Pharma is issuing the following operational update today:

  • New management appointed, with Thomas Olin as interim CEO and Björn Petersson as CFO
  • New website launched on July 16, 2026
  • The Board of Directors intends to call an extraordinary general meeting. The meeting is scheduled to be held in September with the following main items on the agenda
    • election of auditor
    • amendment of the Articles of Incorporation to allow for the necessary capital raising for the preparation of coming clinical study
    • reasons for and authorization of the aforementioned capital raising
    • resolution regarding the Nomination Committee

Detailed information regarding the extraordinary general meeting will be provided in the upcoming notice.

About Novakand Pharma AB (publ)
Novakand Pharma is a clinical stage biotechnology company developing a new class of small-molecule orphan drugs for cancer.

For more information:
Visit the company’s website at www.novakand.com or contact ir@novakand.com

Attachments


Novakand Pharma Provides an Operational Update Regarding Management, Website, and Planned Extraordinary General Meeting